Company / SG&A Expense
Arcutis Biotherapeutics, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$274.6M
FY2025
5-year range
$61.0M / $274.6M
FY2021-FY2025
Trend
+19.7%
vs FY2024
Sector context
#60 of 213
Health Care
What the data says
At $275M, Arcutis Biotherapeutics, Inc.'s sg&a expense ranks #154 of 213 in the Health Care sector. SG&A Expense has increased for 7 consecutive years, from $2M in FY2018 to $275M in FY2025.
Based on SEC 10-K filings.
$275M in FY2025 with a 5-year CAGR of +66.7%.
Increased from $185M to $275M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +31.0%
- 5-Year CAGR
- +66.7%
- 10-Year CAGR
- -
Sector benchmark
#154 of 213 in Health CareTop 72% of 213This company $274.6M Sector average $722.3M
▼
-62.0% below sector average
Key checks
Key Insights
- Arcutis Biotherapeutics, Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +66.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 19.7% year-over-year.
- Ranks #60 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $274.6M | +19.7% |
| FY2024 | $229.4M | +23.9% |
| FY2023 | $185.1M | +51.6% |
| FY2022 | $122.1M | +100.3% |
| FY2021 | $61.0M | +185.8% |
| FY2020 | $21.3M | +222.8% |
| FY2019 | $6.6M | +268.2% |
| FY2018 | $1.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026